Comprender la promoción farmacéutica y responder a ella - Multiple ...

84 | Comprender la promoción farmacéutica y responder a ella - una guía prácticaMaestri E, Furlani G, Suzzi F et al. (2000). So much time for so little: Italy’s pharmaceutical industry and doctors'information needs. British Medical Journal, 320:55.McCormick BB, Tomlinson G, Brill-Edwards P et al. (2001). Effect of restricting contact between pharmaceuticalcompany representatives and internal medicine residents on post training attitudes and behavior. Journal of theAmerican Medical Association, 286:1994-1999.Merck (2001). 3T99 refocus for Vioxx.Mintzes B (2005). Educational initiatives for medical and pharmacy students about drug promotion: An internationalcross-sectional survey. (Puede verse un resumen en español en:http://www.boletinfarmacos.org/042007/investigacionesA.asp, Ginebra, Organización Mundial de la Salud y AcciónInternacional para la Salud).Moghimi Y (2006). The “PharmFree” campaign: Educating medical students about industry influence. PublicLibrary of Science Medicine, 3(1):e30.Muijrers PE, Grol RP, Sijbrandij J et al. (2005). Differences in prescribing between GPs: impact of the cooperationwith pharmacists and impact of visits from pharmaceutical industry representatives. Family Practice 22(6):624-30 (http://www.fampra.oxfordjournals.org/cgi/content/full/22/6/624, se tuvo acceso el 17 de abril de 2009).Norris P, Herxheimer A, Lexchin J et al. (2005). Drug promotion: what we know, what we have yet to learn.Ginebra, Organización Mundial de la Salud y Acción Internacional para la Salud.O’Keefe DJ (2002). Persuasion: theory & research. 2nd ed. Thousand Oaks, California, Sage.Oldani MJ (2004). Thick prescriptions: toward an interpretation of pharmaceutical sales practices. MedicalAnthropology Quarterly, 8(3):325-356.Oxman AD, Thomson MA, Davis DA et al. (1995). No magic bullets: a systematic review of 102 trials of interventionsto improve professional practice. Canadian Medical Association Journal, 153:1423-1431.Peay MY, Peay ER (1988). The role of commercial sources in the adoption of a new drug. Social Science andMedicine, 26(12):1183-1189.Prosser H, Almond S, Walley T (2003). Influences on GPs’ decisions to prescribe new drugs – the importance ofwho says what. Family Practice, 20(1):61-68.Prosser H and Walley T (2003). New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudesand approach. Family Practice 20(5):583-91 (http://www.fampra.oxfordjournals.org/cgi/content/full/20/5/583, setuvo acceso el 17 de abril de 2009).Relman S (2001). Separating continuing medical education from pharmaceutical marketing. Journal of the AmericanMedical Association, 285(15):2009-2012.Republic of South Africa (1965) Medicines and related substances control amendment act (Act 101 of 1965) asamended (http://www.mccza.com, se tuvo acceso el 17 de abril de 2009).Rogers WA, Mansfield PR, Braunack-Mayer AJ et al. (2004). The ethics of pharmaceutical industry relationshipswith medical students. Medical Journal of Australia, 180:411-414.Roughead EE, Gilbert AL, Harvey KJ (1998). Self-regulatory codes of conduct: are they effective in controllingpharmaceutical representatives' presentations to general medical practitioners? International Journal of HealthServices, 28(2):269-279.Roughead EE, Harvey KJ, Gilbert AL (1998a). Commercial detailing techniques used by pharmaceutical representativesto influence prescribing. Australia and New Zealand Journal of Medicine, 28(3):306-310.Sandberg WS, Carlos R, Sandberg EH et al. (1997). The effect of educational gifts from pharmaceutical firms onmedical students’ recall of company names or products. Academic Medicine, 72:916-918.